108 related articles for article (PubMed ID: 10760375)
1. Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions.
Rubino T; Vigano' D; Massi P; Spinello M; Zagato E; Giagnoni G; Parolaro D
Neuropharmacology; 2000 Apr; 39(7):1331-6. PubMed ID: 10760375
[TBL] [Abstract][Full Text] [Related]
2. Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions.
Romero J; Garcia-Palomero E; Castro JG; Garcia-Gil L; Ramos JA; Fernandez-Ruiz JJ
Brain Res Mol Brain Res; 1997 Jun; 46(1-2):100-8. PubMed ID: 9191083
[TBL] [Abstract][Full Text] [Related]
3. Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940.
Rubino T; Viganò D; Massi P; Parolaro D
J Neurochem; 2000 Nov; 75(5):2080-6. PubMed ID: 11032897
[TBL] [Abstract][Full Text] [Related]
4. Chronic Delta9-tetrahydrocannabinol treatment produces antinociceptive tolerance in mice without altering protein kinase A activity in mouse brain and spinal cord.
Dalton GD; Smith FL; Smith PA; Dewey WL
Biochem Pharmacol; 2005 Jul; 70(1):152-60. PubMed ID: 15913565
[TBL] [Abstract][Full Text] [Related]
5. In vivo characterization of the specific cannabinoid receptor antagonist, SR141716A: behavioral and cellular responses after acute and chronic treatments.
Rubino T; Viganò D; Zagato E; Sala M; Parolaro D
Synapse; 2000 Jan; 35(1):8-14. PubMed ID: 10579803
[TBL] [Abstract][Full Text] [Related]
6. Cellular mechanisms of Delta 9-tetrahydrocannabinol behavioural sensitization.
Rubino T; Viganò D; Massi P; Parolaro D
Eur J Neurosci; 2003 Jan; 17(2):325-30. PubMed ID: 12542669
[TBL] [Abstract][Full Text] [Related]
7. The role of several kinases in mice tolerant to delta 9-tetrahydrocannabinol.
Lee MC; Smith FL; Stevens DL; Welch SP
J Pharmacol Exp Ther; 2003 May; 305(2):593-9. PubMed ID: 12606657
[TBL] [Abstract][Full Text] [Related]
8. Loss of cannabinoid-stimulated guanosine 5'-O-(3-[(35)S]Thiotriphosphate) binding without receptor down-regulation in brain regions of anandamide-tolerant rats.
Rubino T; Viganò D; Costa B; Colleoni M; Parolaro D
J Neurochem; 2000 Dec; 75(6):2478-84. PubMed ID: 11080200
[TBL] [Abstract][Full Text] [Related]
9. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study.
Oviedo A; Glowa J; Herkenham M
Brain Res; 1993 Jul; 616(1-2):293-302. PubMed ID: 8395305
[TBL] [Abstract][Full Text] [Related]
10. Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral Delta9-tetrahydrocannabinol in rats.
Rubino T; Sala M; Viganò D; Braida D; Castiglioni C; Limonta V; Guidali C; Realini N; Parolaro D
Neuropsychopharmacology; 2007 Sep; 32(9):2036-45. PubMed ID: 17287821
[TBL] [Abstract][Full Text] [Related]
11. Ras/ERK signalling in cannabinoid tolerance: from behaviour to cellular aspects.
Rubino T; Forlani G; Viganò D; Zippel R; Parolaro D
J Neurochem; 2005 May; 93(4):984-91. PubMed ID: 15857401
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of haloperidol and clozapine on [(3)H]cAMP binding, protein kinase A (PKA) activity, and mRNA and protein expression of selective regulatory and catalytic subunit isoforms of PKA in rat brain.
Dwivedi Y; Rizavi HS; Pandey GN
J Pharmacol Exp Ther; 2002 Apr; 301(1):197-209. PubMed ID: 11907174
[TBL] [Abstract][Full Text] [Related]
13. The effects of delta 9-tetrahydrocannabinol and other cannabinoids on cAMP accumulation in synaptosomes.
Little PJ; Martin BR
Life Sci; 1991; 48(12):1133-41. PubMed ID: 1848340
[TBL] [Abstract][Full Text] [Related]
14. Sex-specific alterations in hippocampal cannabinoid 1 receptor expression following adolescent delta-9-tetrahydrocannabinol treatment in the rat.
Silva L; Harte-Hargrove L; Izenwasser S; Frank A; Wade D; Dow-Edwards D
Neurosci Lett; 2015 Aug; 602():89-94. PubMed ID: 26118897
[TBL] [Abstract][Full Text] [Related]
15. The differential response of protein kinase A to cyclic AMP in discrete brain areas correlates with the abundance of regulatory subunit II.
Ventra C; Porcellini A; Feliciello A; Gallo A; Paolillo M; Mele E; Avvedimento VE; Schettini G
J Neurochem; 1996 Apr; 66(4):1752-61. PubMed ID: 8627334
[TBL] [Abstract][Full Text] [Related]
16. Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence.
González S; Fernández-Ruiz J; Di Marzo V; Hernández M; Arévalo C; Nicanor C; Cascio MG; Ambrosio E; Ramos JA
Drug Alcohol Depend; 2004 May; 74(2):159-70. PubMed ID: 15099659
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment.
Rodríguez de Fonseca F; Gorriti MA; Fernández-Ruiz JJ; Palomo T; Ramos JA
Pharmacol Biochem Behav; 1994 Jan; 47(1):33-40. PubMed ID: 8115426
[TBL] [Abstract][Full Text] [Related]
18. Development of behavioral tolerance to delta 9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain.
Abood ME; Sauss C; Fan F; Tilton CL; Martin BR
Pharmacol Biochem Behav; 1993 Nov; 46(3):575-9. PubMed ID: 8278434
[TBL] [Abstract][Full Text] [Related]
19. Chronic exposure to delta 9-tetrahydrocannabinol fails to irreversibly alter brain cannabinoid receptors.
Westlake TM; Howlett AC; Ali SF; Paule MG; Scallet AC; Slikker W
Brain Res; 1991 Mar; 544(1):145-9. PubMed ID: 1649662
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of protein kinase A and cyclic AMP response element (CRE)-specific transcription factor binding by delta9-tetrahydrocannabinol (delta9-THC): a putative mechanism of cannabinoid-induced immune modulation.
Koh WS; Crawford RB; Kaminski NE
Biochem Pharmacol; 1997 May; 53(10):1477-84. PubMed ID: 9260875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
